How to follow-up a patient who received tocilizumab in severe COVID-19: a case report.

Regina B PodlasinJustyna Dominika KowalskaAndrzej PihowiczBeata Wojtycha-KwaśnicaMagdalena ThompsonTomasz DydaHanna Czeszko-PaprockaAndrzej Horban

Published in: European journal of medical research (2020)

An overlapping effect of hyperinflammation, hypoxic organ injury and drug-related toxicity warrants a long-term follow-up for COVID-19 survivors. In addition, residual IL-6 receptors blockage may mask new infections. A standardized approach to follow-up for COVID-19 survivors is urgently needed. Current and future research should also investigate the impact of experimental therapies on lung tissue healing and regeneration, as well as long-term treatment toxicities.

Keyphrases

coronavirus disease
sars cov
young adults
stem cells
rheumatoid arthritis
respiratory syndrome coronavirus
oxidative stress
case report
early onset
obstructive sleep apnea
smoking cessation
positive airway pressure